Drug intelligence / Profile preview

AIG-Onco1

Development stage: Discontinued
Lead developer: AIGEN Sciences
Modality: Small Molecules

Overview

AIG-Onco1 is a small molecule drug developed by Aigen Sciences for oncology indications. It functions as a KRAS inhibitor, specifically targeting the GTPase KRas protein. The drug was designed to interfere with the activity of mutant KRAS proteins that drive tumor growth in various cancers. Its primary development focus was on neoplasms, particularly colonic cancer and pancreatic cancer. As of June 2025, development has been discontinued at the preclinical stage[1][2][9].

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on AIG-Onco1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIG-Onco1.

Explore the full profile